Sort

Search

01/01/2025 Prospective View of Emicizumab Treatment According Thrombin Generation Time
Vilalta, N, Triquell, M, Llobet, D, Simón, M, Cerdà, N, Carrasco, M, Mateo, J. Prospective View of Emicizumab Treatment According Thrombin Generation Time. HAEMOPHILIA. 2025; 31DOI:. PMID:. IF:3.000(Q2/4D).
01/01/2025 Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease
López-Yerena, A, Villaplana, VD, Badimon, L, Vilahur, G, Padro, T. Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease. Nutrients. 2025; 17(1)DOI:10.3390/nu17010052. PMID:39796486. IF:5.000(Q1/2D).
01/01/2025 Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
Gourdy, P, Bonadonna, RC, Mauricio, D, Müller-Wieland, D, Mauquoi, C, Vera, C, Bonnemaire, M, Freemantle, N. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. DIABETES OBESITY & METABOLISM. 2025; 27(1)DOI:10.1111/dom.16008. PMID:39420531. IF:5.700(Q1/2D).
01/01/2025 Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
Giordano, A, Pérez-Martínez, I, Gisbert, JP, Ricart, E, Martín-Arranz, MD, Mesonero, F, Parga, MLD, Rivero, M, Iglesias, E, Fernández-Prada, S, Calafat, M, Villarino, MTA, Turrión, MAD, Hernández-Camba, A, Lidón, RV, Carpio, D, Brunet, E, Moranta, FR, García, LA, Cuquerella, JT, Bermejo, F, Madero, L, Esteve, M, González-Muñoza, C, Martínez-Montiel, P, Huguet, JM, Calle, JLP, Rodríguez-Lago, I, Ausín, MS, Poyatos, RHL, García-Bosch, O, Marín, GS, Taxonera, C, Ponferrada-Diaz, A, Barreiro-de Acosta, M, Bujanda, L, Serra, RB, Ramos, L, Vera, I, Abizanda, ES, Piqueras, M, Gómez, CS, García-Sepulcre, MF, Arregui, MV, Murillo, NR, Llaó, J, Lucendo, AJ, Marín-Jiménez, I, Camps-Aler, B, Villafranca, CM, Ceballos, D, Ver, Y, Fernández-Salazar, LI, Alcaín, G, Valldosera, G, Andrés, PR, Martínez-Flores, C, Coronel, AF, Ginard, D, García, L, Gomez, IB, Argueelles-Arias, F, Miyashiro, EI, de la Piscina, PR, Villalba, LH, Notari, PA, Martínez-Pérez, TD, Fernández, H, Gilabert, P, Rosas, CM, Nos, P, Gil, JL, López, VMN, Muñoz, F, Palomares, MTDL, Lucio, AS, Merino, O, de Prado, IN, Leal, C, de Carpi, JM, Sánchez, LB, Arce, NM, Frago, S, Mateu, BB, Domènech, E, Planella, EG. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2025; 120(1)DOI:10.14309/ajg.0000000000003207. PMID:39745305. IF:7.600(Q1/1D).
01/01/2025 Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis
Diaz-Ruiz, R, Poca, M, Roman, E, Panadero-Gomez, R, Cuyàs, B, Bañares, I, Morales, A, Puerto, M, Lopez-Esteban, R, Blazquez, E, Fernández-Castillo, M, Correa-Rocha, R, Rapado-Castro, M, Breton, I, Bañares, R, Soriano, G, Garcia-Martinez, R. Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis. Nutrients. 2025; 17(2)DOI:10.3390/nu17020226. PMID:39861356. IF:5.000(Q1/2D).
01/01/2025 Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Machuca, I, Dominguez, A, Amaya, R, Arjona, C, Gracia-Ahufinger, I, Carralon, M, Giron, R, Gea, I, De Benito, N, Martin, A, Galan, F, Martinez, JA, Iglesias, R, Revuelto, J, Caston, JJ, Cano, A, Ruiz-Arabi, E, Martínez-Martínez, L, Torre-Cisneros, J. Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study). Infectious Diseases and Therapy. 2025; 14(1)DOI:10.1007/s40121-024-01077-z. PMID:39612160. IF:5.300(Q1/2D).
01/01/2025 Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria (vol 13, 874, 2024)
Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria (vol 13, 874, 2024). Antibiotics-Basel. 2025; 14(1)DOI:10.3390/antibiotics14010004. PMID:39858394. IF:4.600(Q1/2D).
01/01/2025 EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo, F, Lescoat, A, Conaghan, PG, Bertoldo, E, Colic, J, Santiago, T, Suliman, YA, Matucci-Cerinic, M, Gabrielli, A, Distler, O, Hoffmann-Vold, AM, Castellví, I, Balbir-Gurman, A, Vonk, M, Ananyeva, L, Rednic, S, Tarasova, A, Ostojic, P, Boyadzhieva, V, El Aoufy, K, Farrington, S, Galetti, I, Denton, CP, Kowal-Bielecka, O, Mueller-Ladner, U, Allanore, Y. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84(1)DOI:10.1136/ard-2024-226430. PMID:39874231. IF:20.600(Q1/1D).